Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -296.64% | 30.52% | 30.52% | -182.84% |
| Total Depreciation and Amortization | -- | -73.26% | -30.66% | -28.52% | -17.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 2,668.95% | -70.61% | -74.55% | -91.16% |
| Change in Net Operating Assets | -- | 907.87% | -406.59% | -406.59% | 148.68% |
| Cash from Operations | -- | 28.18% | 3.29% | 3.29% | -158.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 2,005.77% | -1,638.33% | 28.33% | -3.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 51.18% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 1,813.46% | 2,111.67% | 2,111.67% | -62.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 99.54% | 95.90% | 95.90% | -106.44% |